PRELIMINARY CLINICAL DATA FROM A PHASE 1B STUDY OF MAVORIXAFOR AND IBRUTINIB IN PATIENTS WITH WALDENSTRöM MACROGLOBULINEMIA WITH MYD88 AND CXCR4 MUTATIONS. (17th June 2021) - Treon, S.; Buske, C.; Thomas, S.; Branagan, A.; Dimopoulos, M.; Castillo, J. J.; Garzon, F.; Tang, W.; Ronan, R.; Seyffert, S.; Garg, V.; Ali, S.; et al.